The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells

  • Br J Haematol. 2015 Jul;170(1):134-8. doi: 10.1111/bjh.13278.
Yang Cao  1  2 Guang Yang  1  2 Zachary R Hunter  1  3  4 Xia Liu  1  2 Lian Xu  1 Jie Chen  1 Nickolas Tsakmaklis  1 Evdoxia Hatjiharissi  3  4 Sandra Kanan  1 Matthew S Davids  1  2 Jorge J Castillo  1  2 Steven P Treon  5  6
Affiliations
  • 1. Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA.
  • 2. Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • 3. Department of Pathology, Boston University Medical Center, Boston, MA, USA.
  • 4. Theagenio Cancer Hospital, Thessaloniki, Greece.
  • 5. Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute, Boston, MA, USA. [email protected].
  • 6. Department of Medicine, Harvard Medical School, Boston, MA, USA. [email protected].
Keywords
ABT-199; BCL2; CXCR4; Ibrutinib; Waldenström macroglobulinemia.
Products